Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? yes (in some cases)

Internal and Emergency Medicine

Volumn 3, Issue 3, 2008, Pages 201-203

  Meroni, Pier Luigi ^a,b   Gerosa, Maria ^a,b   Chighizola, Cecilia ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; BLOOD; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; NOTE; PRIMARY PREVENTION; RISK FACTOR; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; PRIMARY PREVENTION; RISK FACTORS; THROMBOSIS;

EID: 58149196446     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-008-0170-y     Document Type: Article

References (24)

1. Ruiz-Irastorza G, Hunt BJ, Khamashta MA (2007) A systematic review of secondary thromboprophylaxis in patients with anti-phospholipid antibodies. Arthritis Rheum 57:1487-1495
2. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD (2001) High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 44:1466-1469
3. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD (2002) A cross sectional study of clinical trombotic risks factors and preventive treatments in antiphospholipid syndrome. Rheumatology 41:924-929
4. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD (2007) Aspirin for primary thrombosis prevention in the anti-phospholipid syndrome: a randomized, double-blind, placebo- controlled trial in asymptomatic antiphospholipid antibody-posi tive individuals. Arthritis Rheum 56:2382-2391
5. Hereng T, Lambert M, Hachulla E, Samor M, Dubucquoi S, Caron C, Launay D, Morell-Dubois S, Queyrel V, Hatron PY (2008) Influence of aspirin on the clinical outcomes of 103 anti- phospholipid antibodies-positive patients. Lupus 17:11-15
6. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295-306
7. Galli M, Luciani D (2003) Lupus anticoagulants are stronger risk factors of thrombosis than anti-cardiolipin antibodies in the anti-phospholipid syndrome: a systematic review of the literature. Blood 101:1827-1832
8. Galli M, Luciani D, Bertolini G, Barbui T (2003) Anti-beta 2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 102:2717- 2723
9. Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchioli R, Wisloff F, Marziali S, Morboeuf O, Barbui T (2007) Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study Blood 110:1178-83
10. Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V (2008) Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 5 [Epub ahead of print]
11. Giron-Gonzalez JA, Garcia Del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A (2004) Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31:1560-1567
12. Rosove MH, Brewer PM (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117:303-308
13. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK (1993) Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52:689-692
14. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995) The management of thrombosis in the anti-phospholipid-antibody syndrome. N Engl J Med 332:993-997
15. Shah NM, Khamashta MA, Atsumi T, Hughes GR (1998) Outcome of patients with anticardiolipin antibodies: a 10-year follow-up of 52 patients. Lupus 7:3-6
16. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D'Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 100:530-536
17. Erkan D (2006) Lupus and thrombosis. J Rheumatol 33:1715- 1717
18. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP (2000) Prophylactic Antithrombotic Therapy for Patients With Systemic Lupus Erythematosus With or Without Antiphospholipid Antibodies Do the Benefits Outweigh the Risks? A Decision Analysis. Arch Intern Med 160:2042-2048
19. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Matucci Cerinic M, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337-3347
20. Ostrowski RA, Robinson JA (2008) Antiphospholipid antibody syndrome and autoimmune diseases. Hematol Oncol Clin N Am 22:53-65
21. Diz-Küçükkaya R, Hacihanefioǧlu A, Yenerel M, Turgut M, Keskin H, Nalçaci M, Inanç M (2001) Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 98:1760-1764
22. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S (2005) Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 351:260-267
23. Erkan D, Patel S, Nuzzo M, Gerosa M, Tincani A, Meroni PL, Lockshin M (2008) Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. Rheumatology (in press)
24. Roubey RA (2003) New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 48:3004-3008